BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...is developing an anti-CD39 mAb, since its spinout from Tizona Therapeutics Inc. last year.Ophthalmic company Oxurion N.V....
...central lab solutions for EMEA at the Siemens Healthineers unit of Siemens AG (Xetra:SIE). BC Staff Trishula Therapeutics Oxurion N.V. Eisai...
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...Jacobsmas chief development officer. Jacobs was VP, clinical development and medical affairs at Osmotica Pharmaceutical Corp.Oxurion N.V....
BioCentury | Feb 26, 2020
Deals

Bicycle’s bicyclic peptides attract Genentech as first corporate immuno-oncology partner

...deal with ThromboGenics N.V. to develop its peptides for ophthalmic diseases. ThromboGenics, now known as Oxurion N.V....
BioCentury | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

...Oxurion misses in macular edema trial Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that...
...endothelial growth factor A Mary Romeo, Assistant Editor and Paul Bonanos, Associate Editor Acelarin (MTL-007, NUC-1031) THR-317 WP1066 Moleculin Biotech Inc. Oxurion N.V. NuCana...
BioCentury | Nov 16, 2018
Company News

Oxurion, Beta Therapeutics partner to develop heparanase inhibitors

...Beta Therapeutics Pty. Ltd., Canberra, Australia Oxurion N.V. (Euronext:OXUR), Leuven, Belgium Business: Ophthalmic Shannon Lehnbeuter Beta Therapeutics Pty. Ltd. Oxurion N.V....
BioCentury | May 4, 2018
Clinical News

ThromboGenics reports Phase I/II data for DME candidate

...of placental growth factor (PGF; PLGF). Lucentis is a a humanized mAb fragment against VEGF-A. ThromboGenics...
...letters or see ≥83 ETDRS letters by study visit Status: Phase I/II data Milestone: NA Allison Johnson THR-317 Oxurion N.V. Placental...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

...second compound, respectively, decreased vascular permeability in the retina compared with vehicle. Next steps by ThromboGenics...
...N.V. could include testing the peptides in additional models of DME. Bicycle Therapeutics Ltd. and ThromboGenics...
...published online March 9, 2018 doi:10.1021/acs.jmedchem.7b01625 CONTACT: Tjing-Tjing Hu, ThromboGenics N.V., Leuven, Belgium email: jean.feyen@thrombogenics.com Hongjiang Li Oxurion N.V. Plasma...
BioCentury | Dec 15, 2017
Clinical News

ThromboGenics stops diabetic retinopathy trial due to slow enrollment

...evaluating ocriplasmin (THR-409) to treat non-proliferative diabetic retinopathy (NPDR) due to slow recruitment rate, which ThromboGenics...
...endpoint is safety. Data from the trial are slated for late 2018 or early 2019. ThromboGenics...
...the EU to treat vitreomacular traction and in the U.S. to treat symptomatic vitreomacular adhesion. ThromboGenics...
BioCentury | Dec 14, 2017
Translation in Brief

STUBbing out thrombosis

Patients with chronic kidney disease are at a higher risk of thrombosis, especially following surgery and dialysis, but are also at a higher risk of bleeding than healthy individuals, making standard antithrombotic therapies dangerous. A...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...Brett Monia to COO from SVP of antisense drug discovery, effective Jan. 15. Ophthalmic company ThromboGenics...
Items per page:
1 - 10 of 304
BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...is developing an anti-CD39 mAb, since its spinout from Tizona Therapeutics Inc. last year.Ophthalmic company Oxurion N.V....
...central lab solutions for EMEA at the Siemens Healthineers unit of Siemens AG (Xetra:SIE). BC Staff Trishula Therapeutics Oxurion N.V. Eisai...
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...Jacobsmas chief development officer. Jacobs was VP, clinical development and medical affairs at Osmotica Pharmaceutical Corp.Oxurion N.V....
BioCentury | Feb 26, 2020
Deals

Bicycle’s bicyclic peptides attract Genentech as first corporate immuno-oncology partner

...deal with ThromboGenics N.V. to develop its peptides for ophthalmic diseases. ThromboGenics, now known as Oxurion N.V....
BioCentury | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

...Oxurion misses in macular edema trial Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that...
...endothelial growth factor A Mary Romeo, Assistant Editor and Paul Bonanos, Associate Editor Acelarin (MTL-007, NUC-1031) THR-317 WP1066 Moleculin Biotech Inc. Oxurion N.V. NuCana...
BioCentury | Nov 16, 2018
Company News

Oxurion, Beta Therapeutics partner to develop heparanase inhibitors

...Beta Therapeutics Pty. Ltd., Canberra, Australia Oxurion N.V. (Euronext:OXUR), Leuven, Belgium Business: Ophthalmic Shannon Lehnbeuter Beta Therapeutics Pty. Ltd. Oxurion N.V....
BioCentury | May 4, 2018
Clinical News

ThromboGenics reports Phase I/II data for DME candidate

...of placental growth factor (PGF; PLGF). Lucentis is a a humanized mAb fragment against VEGF-A. ThromboGenics...
...letters or see ≥83 ETDRS letters by study visit Status: Phase I/II data Milestone: NA Allison Johnson THR-317 Oxurion N.V. Placental...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

...second compound, respectively, decreased vascular permeability in the retina compared with vehicle. Next steps by ThromboGenics...
...N.V. could include testing the peptides in additional models of DME. Bicycle Therapeutics Ltd. and ThromboGenics...
...published online March 9, 2018 doi:10.1021/acs.jmedchem.7b01625 CONTACT: Tjing-Tjing Hu, ThromboGenics N.V., Leuven, Belgium email: jean.feyen@thrombogenics.com Hongjiang Li Oxurion N.V. Plasma...
BioCentury | Dec 15, 2017
Clinical News

ThromboGenics stops diabetic retinopathy trial due to slow enrollment

...evaluating ocriplasmin (THR-409) to treat non-proliferative diabetic retinopathy (NPDR) due to slow recruitment rate, which ThromboGenics...
...endpoint is safety. Data from the trial are slated for late 2018 or early 2019. ThromboGenics...
...the EU to treat vitreomacular traction and in the U.S. to treat symptomatic vitreomacular adhesion. ThromboGenics...
BioCentury | Dec 14, 2017
Translation in Brief

STUBbing out thrombosis

Patients with chronic kidney disease are at a higher risk of thrombosis, especially following surgery and dialysis, but are also at a higher risk of bleeding than healthy individuals, making standard antithrombotic therapies dangerous. A...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...Brett Monia to COO from SVP of antisense drug discovery, effective Jan. 15. Ophthalmic company ThromboGenics...
Items per page:
1 - 10 of 304